RISCHIO DI MORTALITA’ PER LA NASH A SECONDA DEL GRADO DI FIBROSI. UNA GRANDE META-ANALISI DA “CLINICAL GASTROENTEROLOGY & HEPATOLOGY” (FREE)

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis Cheng Han Ng et al. Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis…

RIFAXIMINA PER LA MALATTIA EPATICA DA ALCOL. UN EDITORIALE DA “LANCET” (FREE).

EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Rifaximin-α in alcohol-associated liver disease Chencheng Xie et al Alcohol-associated liver disease is the most common cause of cirrhosis and a leading indication for liver transplantation in the USA and worldwide. A public health concern, the morbidity and mortality of alcohol-associated liver disease has accelerated globally since the COVID-19 pandemic due to rising alcohol consumption.…

LA RIFAXIMINA RIDUCE LA PROGRESSIONE DELLA FIBROSI NELLA MALATTIA EPATICA DA ALCOL ! 1100 MG AL GIORNO PER 18 MESI: RIDUZIONE DEL 20% DI PROGRESSIONE VS PLACEBO odds ratio 0,42 [0·18–0·98]; p=0·044. RCT SU BIOPSIE DA “LANCET” (FREE)

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Mads Israelsen et al. Summary Background Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients…